Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: metoprolol xl Clear all
Completed Phase 4 Interventional Results available

Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life

NCT00999102
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Nebivolol
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 23, 2026, 6:19 AM EDT
Recruiting Phase 4 Interventional

Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score

NCT07490067
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients

NCT01502787
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Forearm blood flow, Microneurography, Rhythmic handgrip exercise, Lower body negative pressure, Angiotensin II
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension

NCT00273052
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol Phosphate modified release formulation, metoprolol succinate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chandler, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 23, 2026, 6:19 AM EDT
Terminated Not applicable Interventional Results available

The Impact of Nebivolol Versus Metoprolol on Quality of Life

NCT01441570
View directory record Official record
Conditions
Transplant; Failure, Kidney, Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional

307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects

NCT00255502
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 23, 2026, 6:19 AM EDT
Terminated Phase 4 Interventional Results available

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

NCT01605370
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses 2

NCT01203852
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Chlorthalidone
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 23, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional Results available

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02587351
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Metoprolol succinate, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 84 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional

Reversal of Ventricular Remodeling With Toprol-XL

NCT00038077
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Seloken ZOK/Toprol-XL, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Sep 23, 2026, 6:19 AM EDT
Not listed Phase 4 Interventional

Coreg CR, Blood Vessel Stiffness and Blood Vessel Function

NCT00732511
View directory record Official record
Conditions
Endothelial Function, Diabetes Mellitus, Hypertension
Interventions
carvedilol, metoprolol extended release
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

NCT00255528
View directory record Official record
Conditions
Hypertension
Interventions
metoprolol succinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 16 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
30
States / cities
Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

NCT01049009
View directory record Official record
Conditions
High Blood Pressure
Interventions
Nebivolol, Metoprolol XL
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients

NCT00648895
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol ER (TM)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 79 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2010 · Synced Sep 23, 2026, 6:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Using Beta Blockers to Treat Mitral Regurgitation

NCT00700947
View directory record Official record
Conditions
Heart Disease, Mitral Regurgitation, Heart Valve Disease, Mitral Valve Insufficiency
Interventions
Beta-blocker therapy (TOPROL-XL® )
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

NCT00953212
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
beta blockers, amiodarone, ascorbic acid
Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and the Endothelin (ET)-1 System

NCT01395329
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 23, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

NCT00123903
View directory record Official record
Conditions
Heart Failure, Congestive and Microalbuminuria
Interventions
metoprolol xl, carvedilol MR, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients

NCT01501929
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol succinate, Nebivolol, Non-invasive measurement of Cardiac Output (CO), Endothelial cell collection, Microvascular perfusion assessment using Definity
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

NCT01595516
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Nebivolol, Metoprolol, Placebo, Bradykinin, Saline, Vitamin C
Drug · Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
45 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells

NCT01041287
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Sep 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Results available

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

NCT01798992
View directory record Official record
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 23, 2026, 6:19 AM EDT